Digital Rehabilitation for Patellofemoral Pain

A physician can take an accurate history, make the right diagnosis, and prescribe an appropriate rehabilitation program inside a single visit. What happens over the eight or twelve weeks that follow is largely invisible. The patient leaves with a set of exercises, a general sense of how often to do them, and a follow-up appointment several weeks away.

That interval is where most musculoskeletal recovery actually happens, and it is where clinical visibility is thinnest. A multicenter randomized controlled trial published in the British Journal of Sports Medicine (BJSM) examined one structured approach to that period: a smartphone-based digital therapeutic for chronic patellofemoral pain combining personalized home exercise with cognitive behavioral support. The trial is worth a physician's attention less because digital rehabilitation is a new idea, and more because this particular program was tested in a randomized design across 10 hospitals with a patient-reported primary endpoint.

What did the randomized controlled trial evaluate?

The study was a multicenter, parallel-group randomized controlled trial conducted through orthopedic outpatient clinics at 10 hospitals in the Republic of Korea. It enrolled 216 participants with chronic patellofemoral pain, defined as anterior or retropatellar knee pain lasting at least three months with activity-related provocation. Participants were randomized either to MORA Cure PFP, a condition-specific digital therapeutic developed by EverEx, or to a control group.

The intervention lasted eight weeks. MORA Cure PFP delivered a personalized home-based exercise program, weekly cognitive behavioral sessions, and daily self-reflective worksheets through a smartphone application. The combination matters clinically: patellofemoral pain is a condition where loading history, kinesiophobia, and pain beliefs often travel together, and the program addressed the exercise and the cognitive components in parallel rather than treating exercise alone as the whole intervention.

The control group received patellofemoral pain education, one-time exercise instruction, printed materials, and self-monitoring exercise diaries. That comparator is close to what many patients receive in routine orthopedic practice, which makes the contrast a practical one rather than a comparison against no care at all. Outcomes were measured at baseline and at weeks 4, 8, and 12. The primary endpoint was usual knee pain at eight weeks, measured on a 0 to 100 mm Visual Analogue Scale.

What did the study find?

On the primary endpoint, the results favored the digital therapeutic group. At eight weeks, the between-group mean difference in usual knee pain was -12.5 mm on the 0 to 100 mm Visual Analogue Scale (95% CI -17.1 to -7.8), favoring MORA Cure PFP. Secondary outcomes moved in the same direction, including worst pain (-10.7 mm, 95% CI -15.9 to -5.4), knee function on the Anterior Knee Pain Scale (+5.2 points, 95% CI 2.7 to 7.7), health-related quality of life on the EQ VAS (+10.7 points, 95% CI 7.1 to 14.4), and pain catastrophizing on the Pain Catastrophizing Scale (-1.8 points, 95% CI -3.3 to -0.3).

Two further findings deserve attention from anyone who has prescribed a home exercise program and wondered what happened to it. Exercise adherence in the trial exceeded 80%, which is high relative to what is commonly reported for unsupervised home programs in musculoskeletal populations. Researchers also reported no device-related or intervention-related serious adverse events over the study period.

Readers should interpret the point estimates alongside their confidence intervals and the study's own discussion of thresholds rather than assuming any single number represents a meaningful change for an individual patient. The full methods, statistical analysis, and author conclusions are available in the BJSM publication and the corresponding PubMed record.

Why does between-visit support matter in musculoskeletal care?

Set the specific trial aside for a moment and the underlying problem is familiar across orthopedic and sports medicine practice. A patient with chronic knee pain might spend forty minutes with a physician over a three-month episode of care. Everything else, including the exercise sessions that were skipped, the flare that started on a Tuesday, and the decision to stop because progress felt too slow, happens outside the encounter and usually arrives as a retrospective summary at the next visit.

Several practical challenges follow from that structure. Home exercise adherence is difficult to sustain once the initial motivation of the appointment fades. Engagement tends to dip in the middle weeks of a program, precisely when progression decisions are being made. Symptom changes that would alter the plan often go unreported. Access is uneven as well, since not every patient can attend supervised rehabilitation at the frequency a plan assumes, whether because of distance, cost, work schedules, or caregiving responsibilities.

None of this implies that a physician should personally monitor every patient interaction between visits. That would be neither realistic nor a good use of clinical time. The more useful framing is whether a structured support layer can sit inside the care pathway, handle routine reinforcement and data collection, and surface the small number of situations that genuinely warrant clinical attention. Technology that increases documentation burden without changing what a clinician can see or decide is not solving the problem it claims to address.

What could these findings mean for physicians?

The BJSM trial adds a randomized data point to a body of evidence around structured digital rehabilitation support. For physicians, the most relevant contribution may not be the size of the pain difference, but the demonstration that a structured, condition-specific program delivered outside the clinic was feasible across 10 hospital-based orthopedic settings, sustained high reported exercise adherence, and produced outcomes that favored the digital therapeutic group across pain, function, quality of life, and pain catastrophizing.

It is also a reminder that the content of between-visit support matters. The intervention tested here was not a library of exercise videos. It combined individualized exercise progression with weekly cognitive behavioral sessions and daily self-reflection, which is closer to a defined treatment program than to a reminder system. For patellofemoral pain in particular, where pain beliefs and activity avoidance frequently shape the clinical course, that design choice is clinically coherent.

The appropriate conclusion is measured. These findings do not establish that every orthopedic or musculoskeletal practice should adopt digital rehabilitation, nor do they tell a physician which product to select. They suggest that structured digital support is a reasonable thing to evaluate for appropriate patients, and that the evaluation should ask what evidence exists for the specific program under consideration and the specific population it was tested in.

What are the important limitations and context of this study?

Knowing where evidence applies, and where it does not, is part of evaluating any healthcare technology. Several boundaries around this trial should shape how it is read.

The study enrolled patients specifically with chronic patellofemoral pain, defined as anterior or retropatellar pain of at least three months with activity-related provocation. The findings should not be generalized automatically to rotator cuff disease, low back pain, knee osteoarthritis, post-operative rehabilitation, or any other orthopedic or musculoskeletal diagnosis. Different conditions have different natural histories, different rehabilitation demands, and different responses to cognitive behavioral components.

The trial was conducted across orthopedic outpatient clinics at 10 hospitals in the Republic of Korea. Care pathways, referral patterns, access to supervised physical therapy, cultural attitudes toward exercise and pain, and baseline standard of care all vary between health systems, so setting is a relevant consideration when applying the results to patient populations elsewhere.

The intervention evaluated was MORA Cure PFP, a condition-specific digital therapeutic. It was not EverEx's current U.S. Remote Therapeutic Monitoring and patient engagement platform, and this trial should not be read as a clinical validation of that platform or of its individual capabilities. Duration is also worth noting: the intervention and primary treatment period lasted eight weeks, with outcomes measured through week 12. That follow-up window is relatively short compared with the course of many chronic musculoskeletal conditions.

Longer-term studies would provide more information about the durability of outcomes after the program ends, whether engagement is sustained beyond a defined intervention period, and how similar approaches perform across broader and more varied patient populations. Taken together, the trial is best interpreted as evidence about this specific intervention in this specific population, not as proof that all forms of digital rehabilitation will produce comparable results.

How does this research connect to EverEx today?

To restate the distinction plainly: MORA Cure PFP is the intervention that was evaluated in the BJSM randomized controlled trial, and it is a separate product from the EverEx Remote Therapeutic Monitoring and patient engagement platform used by physician practices, hospitals, and rehabilitation providers in the United States. The trial results belong to MORA Cure PFP in patients with chronic patellofemoral pain.

What carries across is a principle rather than a product claim. Care and rehabilitation do not stop when a patient leaves the clinic, and the weeks in between are where much of the outcome is determined. That idea shaped the research program behind MORA Cure PFP, and it continues to shape how EverEx builds for physician-led care.

In practice today, EverEx supports physicians and healthcare organizations through digital home exercise programs, Remote Therapeutic Monitoring, patient engagement, symptom reporting, exercise tracking, adherence monitoring, clinician-patient communication, visibility into patient progress between visits, and RTM documentation and workflow support. These capabilities were not individually evaluated in the BJSM trial. They reflect the same underlying objective: giving care teams a structured way to stay connected to patients during the part of recovery that happens at home.

Building the evidence for care beyond the visit

Healthcare technology should be held to the standard physicians apply to everything else in practice: what was studied, in whom, against what comparator, and with what result. Peer-reviewed randomized evidence is one part of that picture, and a single trial in a single population is a starting point rather than a conclusion.

Better technology is not the end goal. Better access to effective care, stronger patient engagement, and better support throughout recovery are the goals, and the technology only matters to the extent it serves them. The clinical relationship between a physician and a patient is the thing being supported here, not the thing being replaced.

The question worth asking of any digital rehabilitation tool is not whether it is sophisticated, but whether it helps a patient do the right things between visits and helps a clinician know when something has changed.

Read the research

Read the full study in the British Journal of Sports Medicine (DOI: 10.1136/bjsports-2025-110863). The record is also indexed on PubMed.

For physicians, orthopedic practices, and health systems evaluating how to support patients between appointments, see how EverEx helps physicians and hospitals extend care beyond the traditional visit. Additional clinical and operational material is available in the EverEx Resource Hub.

Sources

• British Journal of Sports Medicine, multicenter randomized controlled trial of MORA Cure PFP in chronic patellofemoral pain (DOI: 10.1136/bjsports-2025-110863)
• PubMed record, PMID 42692805

This article is intended for educational purposes only and does not constitute medical, legal, billing, or compliance advice. Study findings described here apply to the population and intervention evaluated in the cited research. Clinical decisions should be based on individual patient assessment and current professional guidance.